Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumorsJohn Bisi, Jay C. Strum|Oncotarget|2017Cited by 58